The effects of rituximab therapy on released interferon-γ levels in the quantiferon assay among ra patients with different status of Mycobacterium tuberculosis infection

Rheumatology (United Kingdom)

Volumn 52, Issue 4, 2013, Pages 697-704

  Chen, Yi Ming ^a,b   Chen, Hsin Hua ^a,b   Lai, Kuo Lung ^a,b   Hung, Wei Ting ^a,b   Lan, Joung Liang ^a,b,c   Chen, Der Yuan ^a,b,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Interferon ; QuantiFERON tb gold in tube assay; Rheumatoid arthritis; Rituximab; TNF inhibitors; Tuberculosis

Indexed keywords

ADALIMUMAB; ETANERCEPT; GAMMA INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG HYPERSENSITIVITY; EX VIVO STUDY; FEMALE; HEALTH STATUS; HUMAN; HUMAN CELL; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULIN TEST;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875624029     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes365     Document Type: Article

References (34)

1. Carmona L, Hernandez-Garcia C, Vadillo C et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
2. Gomez-Reino JJ, Carmona L, Valverde VR et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
3. Gardam MA, Keystone EC, Menzies R et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148-55.
4. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005;44: 714-20.
5. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61:62-3.
6. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-72.
7. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10: 1127-32.
8. Chen DY, Shen GH, Chen YM et al. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNg assay. Ann Rheum Dis 2012;71:231-7.
9. Boom WH. The role of T-cell subsets in Mycobacterium tuberculosis infection. Infect Agents Dis 1996;5:73-81.
10. Barnes PF, Wizel B. Type 1 cytokines and the pathogenesis of tuberculosis. Am J Respir Crit Care Med 2000;161: 1773-4.
11. Jurado JO, Pasquinelli V, Alvarez IB et al. IL-17 and IFN-g expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J Leukoc Biol 2012;91:991-1002.
12. Mohan VP, Scanga CA, Yu K et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-55.
13. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
14. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomised, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
15. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 2005;7(Suppl 3): S19-25.
16. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
17. Burr ML, Malaviya AP, Gaston JH, Carmichael AJ, Östör AJK. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology 2008; 47:738-9.
18. Jung N, Owczarczyk K, Hellmann M et al. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology 2008;47:932-3.
19. Kevin L, Winthrop S, Yamashita S, Beekmann E, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis 2008;46: 1738-40.
20. Ulrichs T, Kosmiadi GA, Trusov V et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004;204:217-28.
21. Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007;178:7222-34.
22. Smolen JS, Keystone EC, Emery P et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:143-50.
23. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
24. Hsieh PR, Liu YC, So J et al. Mycobacterium tuberculosis in Taiwan. J Infect 2006;52:77-85.
25. Prevoo MLL, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48.
26. Van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
27. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95.
28. Ogata A, Mori M, Hashimoto S et al. Minimal influence of tocilizumab on IFN-g synthesis by tuberculosis antigens. Mod Rheumatol 2010;20:130-3.
29. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007;13:175-82.
30. Diel R, Loddenkemper R, Meywald-Walter K et al. Predictive value of a whole-blood IFN-{gamma} assay for the development of active TB disease. Am J Respir Crit Care Med 2008;177:1164-70.
31. Hatemi G, Melikoglu M, Ozbakir F et al. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 2012;14: R147.
32. Hamdi H, Mariette X, Godot V et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumor necrosis factor antagonsits. Arthritis Res Ther 2006;8: R114.
33. Tony HP, Burmester G, Schulze-Koops H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13:R75.
34. Caccamo N, Guggino G, Joosten SA et al. Multifunctional CD4 (+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010;40:2211-20.